Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

DANIEL EDWARD KREUTZ

Allopathic & Osteopathic Physicians Internal Medicine Rheumatology

NPI
1275789877
CMS profile
194716
Location
GILBERT, AZ

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$4,256.08

196 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $4,256.08 196

By paying entity

PY2024 · entire year · sorted by reported total

Page 4 of 4; records 151–196 of 196 matching records. This page contains 46 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

DANIEL EDWARD KREUTZ

NPI 1275789877 · CMS profile ID 194716

Allopathic & Osteopathic Physicians / Internal Medicine / Rheumatology

GILBERT, AZ

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 4 of 4; records 151–196 of 196 matching records. This page contains 46 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1275789877?year=2024&recipient=provider&page=4#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
DANIEL EDWARD KREUTZ, NPI 1275789877, CMS profile ID 194716. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 4; records 151–196 of 196 matching records. This page contains 46 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1275789877?year=2024&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). DANIEL EDWARD KREUTZ, NPI 1275789877, CMS profile ID 194716. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 4; records 151–196 of 196 matching records. This page contains 46 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1275789877?year=2024&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
DANIEL EDWARD KREUTZ, NPI 1275789877, CMS profile ID 194716, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 4 of 4; records 151–196 of 196 matching records. This page contains 46 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1275789877?year=2024&recipient=provider&page=4#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

196 matching records · $4,256.08 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 196 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 151–196 of 196.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
UCB, Inc. $21.8803/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1143044759 CMS
PFIZER INC. $15.6803/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131272654 CMS
ABBVIE INC. $31.1303/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104109688 CMS
Novartis Pharmaceuticals Corporation $11.5103/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087076410 CMS
UCB, Inc. $26.6903/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1143044757 CMS
ABBVIE INC. $23.6803/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104109686 CMS
PFIZER INC. $20.6602/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131010030 CMS
Amgen Inc. $21.2502/28/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1111624989 CMS
E.R. Squibb & Sons, L.L.C. $19.3802/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101275539 CMS
ABBVIE INC. $29.5302/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104109682 CMS
ABBVIE INC. $0.8102/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104109684 CMS
UCB, Inc. $15.8802/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1143044755 CMS
ABBVIE INC. $21.1802/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104109680 CMS
UCB, Inc. $0.6302/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1143044753 CMS
ABBVIE INC. $23.0702/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104109678 CMS
Lilly USA, LLC $23.6002/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136141009 CMS
Amgen Inc. $20.9002/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117301889 CMS
Amgen Inc. $29.5402/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1111624975 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $24.3902/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117945375 CMS
Amgen Inc. $26.7502/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1111624963 CMS
Novartis Pharmaceuticals Corporation $13.8202/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087076400 CMS
UCB, Inc. $35.3002/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1143044751 CMS
Amgen Inc. $30.7802/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1111624973 CMS
PFIZER INC. $21.7902/03/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131053058 CMS
Novartis Pharmaceuticals Corporation $15.8302/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087076398 CMS
Amgen Inc. $12.5101/31/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1111624951 CMS
PFIZER INC. $19.8401/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1130977604 CMS
AstraZeneca Pharmaceuticals LP $17.9701/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104229749 CMS
Lilly USA, LLC $23.9601/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136133429 CMS
ABBVIE INC. $24.1901/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104109674 CMS
ABBVIE INC. $1.6701/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104109676 CMS
Amgen Inc. $84.3301/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1111624991 CMS
GlaxoSmithKline, LLC. $16.0401/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1115728437 CMS
Organon Llc $16.8401/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136300418 CMS
ABBVIE INC. $27.0001/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104109672 CMS
AstraZeneca Pharmaceuticals LP $20.2201/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105695366 CMS
Amgen Inc. $15.4301/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1111624961 CMS
Amgen Inc. $25.7901/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1111624987 CMS
UCB, Inc. $19.4801/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1143044749 CMS
AstraZeneca Pharmaceuticals LP $13.4901/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105870251 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $28.9401/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117945379 CMS
ABBVIE INC. $28.1301/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104109670 CMS
E.R. Squibb & Sons, L.L.C. $21.1301/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101275529 CMS
PFIZER INC. $16.2801/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1130948599 CMS
Teva Pharmaceuticals USA, Inc. $13.2601/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1151646833 CMS
UCB, Inc. $11.9601/03/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1143044747 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $3,684.31 238
PY2020 $3,792.24 135
PY2021 $3,461.97 187
PY2022 $3,755.53 201
PY2023 $4,168.67 193
PY2024 $4,256.08 196
PY2025 $3,924.87 179

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $433,651.75 51
PY2024 Principal investigator $275,042.27 52
PY2023 Principal investigator $211,719.06 103
PY2022 Principal investigator $236,375.35 123
PY2021 Principal investigator $609,978.67 188
PY2020 Principal investigator $453,001.76 154
PY2019 Principal investigator $304,172.64 95

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

51 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $7,757.10 12/29/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202532110
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $4,351.10 12/08/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH PLLC
Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) No dispute reported 06/30/2026 1246430766
Principal investigator 1 ABBVIE INC. $3,878.55 12/04/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202526850
Principal investigator 1 ABBVIE INC. $95.00 12/04/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202527844
Principal investigator 1 ABBVIE INC. $396.90 11/26/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202525584
Principal investigator 1 ABBVIE INC. $106.65 11/26/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202525616
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $8,580.00 11/07/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH PLLC
Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) No dispute reported 06/30/2026 1246430760
Principal investigator 1 ABBVIE INC. $313.20 10/21/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202517477
Principal investigator 1 ABBVIE INC. $4,760.00 08/21/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202505317
Principal investigator 1 ABBVIE INC. $4,080.00 08/14/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202504561
Principal investigator 1 ABBVIE INC. $8,160.00 08/14/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202504563
Principal investigator 1 ABBVIE INC. $3,100.00 08/05/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202501108
Principal investigator 1 Amgen Inc. $2,150.73 07/28/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS & RHEUMATOLOGY ASSOCIATES, P.C
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjgren's Syndrome With Moderate-to-severe Systemic Disease Activity No dispute reported 06/30/2026 1246639181
Principal investigator 1 Amgen Inc. $37,472.55 07/25/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjgren's Syndrome With Moderate-to-severe Systemic Disease Activity No dispute reported 06/30/2026 1246639295
Principal investigator 1 AstraZeneca UK Limited $1,899.00 07/18/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH PLLC
A Multicenter Randomized Double-blind Placebo-controlled Phase 3 Study Evaluating the Efficacy and Safety of Subcutaneous Anifrolumab in Adult Patients with Systemic Lupus Erythematosus No dispute reported 06/30/2026 1185542089
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $1,899.30 07/11/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH PLLC
Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) No dispute reported 06/30/2026 1246430746
Principal investigator 1 ABBVIE INC. $197.10 07/10/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202497862
Principal investigator 1 Amgen Inc. $41,779.80 07/09/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH
A Multicenter, Open-Label, Long-term, Extension Study to Evaluate the Safety and Tolerability of Dazodalibep in Participants With Sjgren's Syndrome (SS) No dispute reported 06/30/2026 1246639271
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $663.00 07/02/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH PLLC
Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) No dispute reported 06/30/2026 1246430712
Principal investigator 1 ABBVIE INC. $91.80 06/25/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202492853
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $1,517.23 06/25/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH PLLC
INSPIRE LTE study No dispute reported 06/30/2026 1246430678
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $1,143.99 06/12/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH PLLC
Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) No dispute reported 06/30/2026 1246430802
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $11,217.05 06/11/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH PLLC
Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) No dispute reported 06/30/2026 1246430732
Principal investigator 1 ABBVIE INC. $3,878.55 06/06/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202490619
Principal investigator 1 Amgen Inc. $10,000.00 06/06/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH PLLC
A Multicenter, Open-Label, Long-term, Extension Study to Evaluate the Safety and Tolerability of Dazodalibep in Participants With Sjgren's Syndrome (SS) No dispute reported 06/30/2026 1246639233
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $382.27 05/09/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH PLLC
Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) No dispute reported 06/30/2026 1246430798
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $250.00 05/07/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH PLLC
Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) No dispute reported 06/30/2026 1246430740
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $11,750.00 05/07/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH PLLC
INSPIRE LTE study No dispute reported 06/30/2026 1246430742
Principal investigator 1 ABBVIE INC. $1,364.85 05/06/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202481401
Principal investigator 1 Amgen Inc. $16,372.44 05/05/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS & RHEUMATOLOGY ASSOCIATES
A Multicenter, Open-Label, Long-term, Extension Study to Evaluate the Safety and Tolerability of Dazodalibep in Participants With Sjgren's Syndrome (SS) No dispute reported 06/30/2026 1246639185
Principal investigator 1 Amgen Inc. $57,230.90 04/25/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH PLLC
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjgren's Syndrome With Moderate-to-severe Systemic Disease Activity No dispute reported 06/30/2026 1246639249
Principal investigator 1 UCB SA $43,732.00 04/14/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH
A Multicenter, Randomized, Double-Blind, Risankizumab-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Study Participants with Active Psoriatic Arthritis. No dispute reported 06/30/2026 1246659424
Principal investigator 1 ABBVIE INC. $680.00 04/10/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202475986
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $1,899.30 03/17/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH PLLC
Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) No dispute reported 06/30/2026 1246430754
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $2,809.30 03/14/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH PLLC
Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) No dispute reported 06/30/2026 1246430690
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $2,748.20 03/10/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH PLLC
Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) No dispute reported 06/30/2026 1246430696
Principal investigator 1 ABBVIE INC. $2,870.00 03/06/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND
M23-700 - Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202458792
Principal investigator 1 ABBVIE INC. $3,387.00 03/06/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND
M23-699 - Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202458849
Principal investigator 1 Amgen Inc. $41,947.20 03/03/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND RHEUMATOLOGY ASSOCIATES - GILBERT - 3645 S ROME ST
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjgrens Syndrome With Moderate-to-Severe Systemic Disease Activity No dispute reported 06/30/2026 1246639201
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $4,776.72 03/03/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH PLLC
INSPIRE LTE study No dispute reported 06/30/2026 1246430706
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $179.15 03/03/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH PLLC
INSPIRE LTE study No dispute reported 06/30/2026 1246430792
Principal investigator 1 ABBVIE INC. $90.13 02/26/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND
M23-700 - Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202453992
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $298.68 02/25/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH PLLC
INSPIRE LTE study No dispute reported 06/30/2026 1246430790
Principal investigator 1 ABBVIE INC. $450.00 02/06/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND
M23-700 - Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202447828
Principal investigator 1 ABBVIE INC. $292.10 02/06/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND
M23-700 - Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202447832
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $10,284.30 02/05/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH PLLC
Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) No dispute reported 06/30/2026 1246430714
Principal investigator 1 Amgen Inc. $15,299.55 01/22/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND RHEUMATOLOGY ASSOCIATES - GILBERT - 3645 S ROME ST
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants with Sjgrens Syndrome With Moderate-to-Severe Symptom State No dispute reported 06/30/2026 1246639199
Principal investigator 1 Eli Lilly and Company $43,061.76 01/22/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH
A RANDOMIZED, CONTROLLED PRAGMATIC PHASE 3B/4 STUDY OF BARICITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 1187877163
Principal investigator 1 Amgen Inc. $10,385.45 01/08/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND RHEUMATOLOGY ASSOCIATES - GILBERT - 3645 S ROME ST
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjgren's Syndrome With Moderate-to-severe Systemic Disease Activity No dispute reported 06/30/2026 1246639203
Principal investigator 1 ABBVIE INC. $313.20 01/06/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND
M23-700 - Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202436768
Principal investigator 1 ABBVIE INC. $1,308.65 01/02/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND
M23-700 - Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202434355